4-Vinylguaiacol, an Active Metabolite of Ferulic Acid by Enteric Microbiota and Probiotics, Possesses Significant Activities against Drug-Resistant Human Colorectal Cancer Cells

Yun Luo,Chong-Zhi Wang,Richard Sawadogo,Jinbin Yuan,Jinxiang Zeng,Ming Xu,Ting Tan,Chun-Su Yuan
DOI: https://doi.org/10.1021/acsomega.0c04394
IF: 4.1
2021-02-10
ACS Omega
Abstract:Ferulic acid, a hydroxycinnamic acid, is abundant in vegetables, grains, and medicinal plants. Emerging evidence suggests that ferulic acid may exert beneficial effects against colorectal cancer. However, the anticancer activity of ferulic acid is relatively low, and its metabolism after oral administration is largely unknown. In this study, mimicking the enteric environment, human intestinal microflora and commercial probiotics were used to metabolize ferulic acid to its metabolites, and their anticancer activities were evaluated. Ferulic acid can be biotransformed to 4-vinylguaiacol (2-methoxy-4-vinylphenol), and the contents of ferulic acid and 4-vinylguaiacol in bio-transformed extracts were determined by high-performance liquid chromatography (HPLC). Using the chemotherapy-sensitive cell line HCT-116 and the chemo-resistant cell line HT-29, the cell proliferation was determined by the modified trichrome stain assay. The cell cycle and induction of apoptosis were assayed using flow cytometry. HPLC data showed that there was a marked transformation from ferulic acid to 4-vinylguaiacol, and the conversion rates of intestinal microflora and four probiotics were from 1.3 to 36.8%. Both ferulic acid and 4-vinylguaiacol possessed dose- and time-related anticancer activities on the two cell lines, while 4-vinylguaiacol showed more potent effects than ferulic acid. Interestingly, 4-vinylguaiacol exhibited significantly higher antiproliferative effects on the HT-29 cell line than that on HCT-116. The IC50 of the metabolite 4-vinylguaiacol on HT-29 cells was 350 μM, 3.7-fold higher than its parent compound. The potential of cancer cell growth inhibition of 4-vinylguaiacol was mediated by cell cycle arrest at the G1 phase and induction of apoptosis. Data from this study indicate that the oral administration of ferulic acid offers a promising approach to increase its anticancer activity through gut microbial conversion to 4-vinylguaiacol, and the biotransformation could also be achieved by selected commercial probiotics. 4-Vinylguaiacol is a potential anticancer metabolite from ferulic acid for chemotherapy-resistant colon cancer cells.This article has not yet been cited by other publications.
chemistry, multidisciplinary
What problem does this paper attempt to address?
The main problem this paper attempts to address is the exploration of the process by which ferulic acid is converted into 4-vinylguaiacol under the action of gut microbiota or commercial probiotics, and its anticancer activity against drug-resistant colorectal cancer cells. Specifically, the study aims to: 1. **Evaluate the conversion process**: Assess the ability of human gut microbiota and four commercial probiotics to convert ferulic acid into 4-vinylguaiacol through high-performance liquid chromatography (HPLC) analysis. 2. **Compare anticancer activity**: Compare the antiproliferative effects of ferulic acid and 4-vinylguaiacol on two colorectal cancer cell lines (chemotherapy-sensitive HCT-116 and chemotherapy-resistant HT-29), as well as their effects on the cell cycle and apoptosis. 3. **Explore potential mechanisms**: Investigate the anticancer mechanisms of 4-vinylguaiacol in drug-resistant colorectal cancer cells, particularly how it inhibits cancer cell growth through cell cycle arrest and induction of apoptosis. The research results indicate that 4-vinylguaiacol exhibits significant anticancer activity in inhibiting the proliferation of drug-resistant colorectal cancer cells (such as HT-29 cells), with effects far superior to its precursor compound ferulic acid. This provides a potential pathway for developing new anti-colorectal cancer strategies, especially in addressing drug resistance.